A Phase III, Multi-Center Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) in Surgically Menopausal Women.
Phase of Trial: Phase III
Latest Information Update: 06 Feb 2012
At a glance
- Drugs Testosterone (Primary)
- Indications Decreased libido
- Focus Therapeutic Use
- 06 Feb 2012 Actual patient number (626) added as reported by ClinicalTrials.gov.
- 06 Feb 2012 Actual end date January 2012 added as reported by ClinicalTrials.gov.
- 06 Feb 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.